Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1% [10]

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 1, 2008, Pages 113-115

  Bellini, V ^a   Simonetti, S ^a   Lisi, P ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; CORTICOSTEROID; CYCLOSPORIN A; MESALAZINE; PIMECROLIMUS; PREDNISONE; SULFAMETHOXAZOLE;

AGED; ARTHRALGIA; BACTERIAL INFECTION; BACTERIUM CULTURE; CASE REPORT; CREAM; DISEASE DURATION; DISEASE SEVERITY; DRUG RESPONSE; ELBOW; ERYTHEMA; FEMALE; FOLLOW UP; HASHIMOTO DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; IMMUNOFLUORESCENCE; LEG ULCER; LETTER; LEUKOCYTOCLASTIC VASCULITIS; MYALGIA; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; RHEUMATOID ARTHRITIS; SKIN FLAP; SKIN PAIN; SKIN ULCER; STAPHYLOCOCCUS AUREUS; ULCER HEALING; ULCERATIVE COLITIS; VITILIGO;

ADMINISTRATION, TOPICAL; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OINTMENTS; PYODERMA GANGRENOSUM; TACROLIMUS; TREATMENT OUTCOME;

EID: 37749002266     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02280.x     Document Type: Letter

References (10)

1. Moschella SL. Neutrophilic dermatoses. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. Mosby, London, 2003: 415-418.
2. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005; 53: 273-283.
3. Mrowietz U. Ascomycin macrolactams. J Cutan Med Surg 2001; 5: 22-25.
4. Zuberbier T, Chong SU, Grunow K et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001; 108: 275-280.
5. Lazarus GS, Rocklin RE, David JR. Pyoderma gangrenosum, altered delayed hypersensitivity, and polyarthritis. Arch Dermatol 1972; 105: 46-51.
6. Norris DA, Weston WI, Thorne G, Humbert JR. Pyoderma gangrenosum: abnormal monocyte function corrected in vitro with hydrocortisone. Arch Dermatol 1978; 114: 906-911.
7. Chiba T, Isomura I, Suzuki A, Morita A. Topical tacrolimus therapy for pyoderma gangrenosum. J Dermatol 2005; 32: 199-203.
8. Groves RW, Allen MH, Ross EL, Barker JNWN, MacDonald DM. Tumour-necrosis factor alpha is proinflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol 1995; 132: 345-352.
9. Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stuetz A, Elbe-Burger A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122: 673-684.
10. Billich A, Aschauer H, Aszòdi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: Pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004; 269: 29-35.